Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acne Vulgaris | 51 | 2024 | 302 | 25.820 |
Why?
|
Dermatologic Agents | 21 | 2024 | 278 | 10.070 |
Why?
|
Dermatology | 37 | 2023 | 872 | 6.880 |
Why?
|
Granuloma Annulare | 7 | 2023 | 28 | 5.100 |
Why?
|
Spironolactone | 12 | 2023 | 382 | 4.810 |
Why?
|
Isotretinoin | 15 | 2024 | 114 | 4.270 |
Why?
|
Skin Diseases | 19 | 2023 | 1066 | 4.200 |
Why?
|
Psoriasis | 12 | 2023 | 901 | 4.130 |
Why?
|
Anti-Bacterial Agents | 19 | 2024 | 7172 | 2.560 |
Why?
|
Drug Utilization | 6 | 2020 | 1183 | 2.280 |
Why?
|
Arthritis, Psoriatic | 3 | 2022 | 215 | 1.940 |
Why?
|
Antibiotic Prophylaxis | 5 | 2021 | 638 | 1.750 |
Why?
|
Drug Prescriptions | 8 | 2021 | 1636 | 1.670 |
Why?
|
Dermatitis, Atopic | 4 | 2023 | 654 | 1.630 |
Why?
|
Tetracyclines | 3 | 2023 | 60 | 1.420 |
Why?
|
Mohs Surgery | 4 | 2021 | 197 | 1.410 |
Why?
|
Quality of Life | 11 | 2023 | 12788 | 1.370 |
Why?
|
Off-Label Use | 3 | 2019 | 169 | 1.350 |
Why?
|
Tetracycline | 2 | 2020 | 214 | 1.290 |
Why?
|
Contraception | 3 | 2020 | 359 | 1.250 |
Why?
|
Retinoids | 5 | 2024 | 101 | 1.220 |
Why?
|
Administration, Oral | 12 | 2023 | 3912 | 1.160 |
Why?
|
Telemedicine | 7 | 2022 | 2874 | 1.020 |
Why?
|
Administration, Topical | 7 | 2021 | 689 | 0.990 |
Why?
|
Medicare Part D | 2 | 2019 | 328 | 0.970 |
Why?
|
Humans | 137 | 2024 | 743811 | 0.970 |
Why?
|
Drug Costs | 5 | 2020 | 1105 | 0.960 |
Why?
|
Hidradenitis Suppurativa | 3 | 2023 | 153 | 0.960 |
Why?
|
Severity of Illness Index | 13 | 2023 | 15526 | 0.950 |
Why?
|
Penicillanic Acid | 1 | 2024 | 44 | 0.940 |
Why?
|
Contraceptives, Oral, Combined | 2 | 2021 | 113 | 0.870 |
Why?
|
Condylomata Acuminata | 1 | 2022 | 82 | 0.830 |
Why?
|
Eczema | 2 | 2023 | 231 | 0.830 |
Why?
|
Cosmetics | 1 | 2023 | 97 | 0.810 |
Why?
|
Research Design | 3 | 2023 | 5983 | 0.790 |
Why?
|
Office Management | 1 | 2021 | 14 | 0.780 |
Why?
|
Patient Satisfaction | 3 | 2024 | 3391 | 0.780 |
Why?
|
Reimbursement Mechanisms | 2 | 2017 | 670 | 0.770 |
Why?
|
Propionates | 2 | 2023 | 169 | 0.760 |
Why?
|
Hematologic Neoplasms | 2 | 2023 | 1832 | 0.750 |
Why?
|
Publications | 2 | 2019 | 195 | 0.740 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2021 | 186 | 0.730 |
Why?
|
Abnormalities, Drug-Induced | 2 | 2020 | 317 | 0.730 |
Why?
|
Climate Change | 2 | 2023 | 418 | 0.730 |
Why?
|
Onychomycosis | 1 | 2020 | 47 | 0.730 |
Why?
|
Probiotics | 1 | 2023 | 350 | 0.720 |
Why?
|
Menstruation Disturbances | 1 | 2021 | 148 | 0.710 |
Why?
|
Biological Factors | 1 | 2020 | 164 | 0.690 |
Why?
|
Teratogens | 1 | 2020 | 112 | 0.690 |
Why?
|
Drug Resistance, Microbial | 2 | 2020 | 860 | 0.680 |
Why?
|
Cross-Sectional Studies | 17 | 2024 | 25032 | 0.680 |
Why?
|
United States | 34 | 2023 | 69859 | 0.680 |
Why?
|
Hyperlipidemias | 2 | 2021 | 789 | 0.670 |
Why?
|
Authorship | 1 | 2022 | 271 | 0.670 |
Why?
|
Surgical Wound Infection | 4 | 2021 | 1539 | 0.650 |
Why?
|
Office Visits | 2 | 2020 | 598 | 0.650 |
Why?
|
Fibromyalgia | 1 | 2023 | 388 | 0.640 |
Why?
|
Diet, Protein-Restricted | 1 | 2018 | 71 | 0.640 |
Why?
|
Cicatrix | 1 | 2024 | 763 | 0.620 |
Why?
|
Relative Value Scales | 1 | 2017 | 84 | 0.610 |
Why?
|
Social Stigma | 1 | 2024 | 701 | 0.600 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2023 | 685 | 0.590 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2023 | 2428 | 0.570 |
Why?
|
Potassium | 1 | 2021 | 1336 | 0.570 |
Why?
|
Comparative Effectiveness Research | 1 | 2021 | 680 | 0.540 |
Why?
|
Physician Incentive Plans | 1 | 2017 | 161 | 0.530 |
Why?
|
Drug Substitution | 1 | 2018 | 281 | 0.520 |
Why?
|
Psychometrics | 2 | 2024 | 3000 | 0.520 |
Why?
|
Retrospective Studies | 24 | 2023 | 77410 | 0.520 |
Why?
|
Adult | 38 | 2024 | 213889 | 0.510 |
Why?
|
General Practice | 1 | 2016 | 100 | 0.510 |
Why?
|
Skin Neoplasms | 5 | 2021 | 5691 | 0.510 |
Why?
|
Skin | 6 | 2022 | 4372 | 0.500 |
Why?
|
Patient Care | 1 | 2021 | 638 | 0.500 |
Why?
|
International Classification of Diseases | 1 | 2020 | 866 | 0.500 |
Why?
|
Female | 52 | 2024 | 380020 | 0.500 |
Why?
|
Publishing | 1 | 2022 | 833 | 0.490 |
Why?
|
Health Services | 1 | 2020 | 758 | 0.490 |
Why?
|
Benzoyl Peroxide | 2 | 2024 | 18 | 0.480 |
Why?
|
Drug Industry | 2 | 2020 | 746 | 0.460 |
Why?
|
Drugs, Generic | 2 | 2020 | 421 | 0.460 |
Why?
|
Venous Thrombosis | 1 | 2023 | 1240 | 0.460 |
Why?
|
Health Care Reform | 3 | 2017 | 1261 | 0.450 |
Why?
|
Medicaid | 2 | 2024 | 2736 | 0.440 |
Why?
|
Cohort Studies | 12 | 2023 | 40545 | 0.440 |
Why?
|
Reimbursement, Incentive | 2 | 2017 | 540 | 0.430 |
Why?
|
Patient Admission | 1 | 2020 | 1380 | 0.430 |
Why?
|
Triglycerides | 2 | 2022 | 2453 | 0.420 |
Why?
|
Drug Discovery | 1 | 2020 | 1058 | 0.420 |
Why?
|
Commerce | 1 | 2017 | 592 | 0.410 |
Why?
|
Young Adult | 18 | 2023 | 56392 | 0.410 |
Why?
|
Adolescent | 20 | 2024 | 85729 | 0.400 |
Why?
|
Laser Therapy | 1 | 2018 | 1071 | 0.400 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 4422 | 0.400 |
Why?
|
Databases, Factual | 6 | 2023 | 7729 | 0.390 |
Why?
|
Male | 40 | 2024 | 349776 | 0.390 |
Why?
|
Pain Measurement | 1 | 2021 | 3420 | 0.380 |
Why?
|
Migraine Disorders | 1 | 2023 | 1620 | 0.370 |
Why?
|
Treatment Outcome | 14 | 2023 | 63042 | 0.370 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 1670 | 0.370 |
Why?
|
Staphylococcal Infections | 1 | 2019 | 1400 | 0.360 |
Why?
|
Drug Therapy, Combination | 4 | 2023 | 6487 | 0.360 |
Why?
|
Pulmonary Embolism | 1 | 2023 | 2375 | 0.360 |
Why?
|
Time Factors | 10 | 2021 | 40038 | 0.350 |
Why?
|
Decision Support Techniques | 1 | 2020 | 1956 | 0.350 |
Why?
|
Periodicals as Topic | 2 | 2019 | 1429 | 0.340 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2134 | 0.340 |
Why?
|
Forecasting | 5 | 2019 | 2950 | 0.330 |
Why?
|
Artificial Intelligence | 2 | 2020 | 2210 | 0.320 |
Why?
|
Incidence | 6 | 2023 | 20948 | 0.320 |
Why?
|
Contraceptive Agents, Female | 2 | 2020 | 135 | 0.320 |
Why?
|
Multiple Sclerosis | 1 | 2023 | 3079 | 0.310 |
Why?
|
Healthcare Disparities | 2 | 2020 | 3155 | 0.310 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2021 | 11729 | 0.300 |
Why?
|
Cost-Benefit Analysis | 4 | 2023 | 5388 | 0.300 |
Why?
|
Early Detection of Cancer | 2 | 2020 | 3089 | 0.300 |
Why?
|
Mass Screening | 2 | 2020 | 5251 | 0.300 |
Why?
|
Health Services Accessibility | 8 | 2023 | 5136 | 0.290 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7270 | 0.290 |
Why?
|
Triage | 1 | 2014 | 977 | 0.290 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 9944 | 0.290 |
Why?
|
Middle Aged | 21 | 2024 | 213241 | 0.280 |
Why?
|
Primary Health Care | 2 | 2020 | 4556 | 0.280 |
Why?
|
Air Pollution | 1 | 2020 | 2286 | 0.280 |
Why?
|
Medicare | 3 | 2021 | 6565 | 0.280 |
Why?
|
Child | 15 | 2023 | 77637 | 0.280 |
Why?
|
Physicians | 2 | 2021 | 4569 | 0.270 |
Why?
|
Pain | 1 | 2021 | 4987 | 0.260 |
Why?
|
Referral and Consultation | 2 | 2018 | 3530 | 0.260 |
Why?
|
Antifungal Agents | 2 | 2020 | 729 | 0.250 |
Why?
|
Biopsy | 5 | 2021 | 6750 | 0.250 |
Why?
|
Models, Theoretical | 1 | 2017 | 3587 | 0.250 |
Why?
|
Cortodoxone | 2 | 2023 | 13 | 0.250 |
Why?
|
Vaccines | 2 | 2023 | 823 | 0.240 |
Why?
|
Depression | 2 | 2020 | 7760 | 0.230 |
Why?
|
Outpatients | 2 | 2021 | 1488 | 0.230 |
Why?
|
Melanosis | 1 | 2024 | 78 | 0.220 |
Why?
|
Emergency Service, Hospital | 2 | 2023 | 7658 | 0.210 |
Why?
|
Hyperpigmentation | 1 | 2024 | 112 | 0.210 |
Why?
|
Cost of Illness | 3 | 2021 | 1859 | 0.210 |
Why?
|
Gels | 1 | 2023 | 425 | 0.210 |
Why?
|
Hirsutism | 1 | 2022 | 69 | 0.210 |
Why?
|
Diet | 1 | 2020 | 7930 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3134 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.210 |
Why?
|
Stereotyping | 1 | 2024 | 241 | 0.200 |
Why?
|
Neoplasms | 2 | 2021 | 21675 | 0.200 |
Why?
|
Delphi Technique | 2 | 2022 | 777 | 0.200 |
Why?
|
Health Care Costs | 3 | 2022 | 3207 | 0.200 |
Why?
|
Coal Tar | 1 | 2020 | 17 | 0.190 |
Why?
|
Pandemics | 2 | 2022 | 8385 | 0.190 |
Why?
|
Dietary Supplements | 2 | 2023 | 3292 | 0.190 |
Why?
|
United States Food and Drug Administration | 2 | 2019 | 1582 | 0.190 |
Why?
|
Africa | 1 | 2023 | 672 | 0.190 |
Why?
|
Hypertension | 1 | 2020 | 8480 | 0.180 |
Why?
|
Petrolatum | 1 | 2020 | 8 | 0.180 |
Why?
|
Sexual Abstinence | 1 | 2020 | 16 | 0.180 |
Why?
|
Prevalence | 3 | 2023 | 15211 | 0.180 |
Why?
|
Emollients | 1 | 2020 | 34 | 0.180 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2020 | 28 | 0.180 |
Why?
|
Intrauterine Devices, Copper | 1 | 2020 | 32 | 0.180 |
Why?
|
Contraceptive Devices, Female | 1 | 2020 | 43 | 0.180 |
Why?
|
Tablets | 1 | 2020 | 145 | 0.180 |
Why?
|
Warts | 1 | 2020 | 68 | 0.180 |
Why?
|
Levonorgestrel | 1 | 2020 | 77 | 0.180 |
Why?
|
Policy | 1 | 2024 | 508 | 0.180 |
Why?
|
Patient Acceptance of Health Care | 3 | 2022 | 3020 | 0.180 |
Why?
|
Reproducibility of Results | 4 | 2024 | 19894 | 0.170 |
Why?
|
Personal Satisfaction | 1 | 2024 | 641 | 0.170 |
Why?
|
Health Records, Personal | 1 | 2020 | 124 | 0.170 |
Why?
|
Evidence-Based Medicine | 3 | 2020 | 3608 | 0.170 |
Why?
|
Prostatic Neoplasms | 1 | 2022 | 11059 | 0.170 |
Why?
|
Search Engine | 1 | 2020 | 144 | 0.170 |
Why?
|
Facial Dermatoses | 1 | 2019 | 87 | 0.160 |
Why?
|
Prescriptions | 1 | 2021 | 387 | 0.160 |
Why?
|
Minnesota | 1 | 2019 | 344 | 0.160 |
Why?
|
Nails | 1 | 2020 | 292 | 0.160 |
Why?
|
Professional Staff Committees | 1 | 2017 | 38 | 0.160 |
Why?
|
Gender Identity | 1 | 2023 | 686 | 0.160 |
Why?
|
Drug Combinations | 1 | 2023 | 1958 | 0.160 |
Why?
|
Poisson Distribution | 1 | 2019 | 513 | 0.150 |
Why?
|
Qualitative Research | 3 | 2021 | 2682 | 0.150 |
Why?
|
Liver Function Tests | 1 | 2019 | 529 | 0.150 |
Why?
|
Condoms | 1 | 2020 | 323 | 0.150 |
Why?
|
Tacrolimus | 1 | 2021 | 743 | 0.150 |
Why?
|
Personnel Selection | 1 | 2019 | 190 | 0.150 |
Why?
|
Health Policy | 2 | 2020 | 2662 | 0.150 |
Why?
|
Esthetics | 1 | 2018 | 305 | 0.150 |
Why?
|
Pruritus | 1 | 2020 | 361 | 0.140 |
Why?
|
Epidemiologic Studies | 1 | 2020 | 676 | 0.140 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 1680 | 0.140 |
Why?
|
Pathology, Clinical | 1 | 2020 | 368 | 0.140 |
Why?
|
Efficiency | 1 | 2019 | 462 | 0.140 |
Why?
|
Health Care Surveys | 3 | 2021 | 2453 | 0.140 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15142 | 0.140 |
Why?
|
Propensity Score | 1 | 2023 | 1781 | 0.140 |
Why?
|
Sex Factors | 2 | 2020 | 10394 | 0.130 |
Why?
|
Remote Consultation | 1 | 2018 | 239 | 0.130 |
Why?
|
Attitude of Health Personnel | 2 | 2021 | 3839 | 0.130 |
Why?
|
Phototherapy | 1 | 2018 | 377 | 0.130 |
Why?
|
Alopecia | 1 | 2019 | 382 | 0.130 |
Why?
|
Australia | 1 | 2018 | 1167 | 0.130 |
Why?
|
Vitamins | 1 | 2023 | 1622 | 0.130 |
Why?
|
Checklist | 1 | 2022 | 832 | 0.130 |
Why?
|
Drainage | 1 | 2021 | 1142 | 0.130 |
Why?
|
Microscopy | 1 | 2020 | 896 | 0.120 |
Why?
|
Tetrazoles | 1 | 2020 | 834 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2021 | 953 | 0.120 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3677 | 0.120 |
Why?
|
Breast Neoplasms | 1 | 2022 | 20827 | 0.120 |
Why?
|
Carcinoma, Basal Cell | 1 | 2020 | 545 | 0.120 |
Why?
|
Administration, Cutaneous | 1 | 2016 | 710 | 0.120 |
Why?
|
Patient Preference | 1 | 2021 | 889 | 0.120 |
Why?
|
Aged | 11 | 2023 | 163178 | 0.120 |
Why?
|
Sexual Behavior | 1 | 2023 | 2049 | 0.120 |
Why?
|
Cluster Analysis | 1 | 2021 | 2712 | 0.120 |
Why?
|
Immunologic Factors | 1 | 2023 | 1580 | 0.120 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 1676 | 0.120 |
Why?
|
Counseling | 1 | 2021 | 1523 | 0.110 |
Why?
|
Risk Assessment | 3 | 2019 | 23327 | 0.110 |
Why?
|
Physicians, Primary Care | 1 | 2020 | 592 | 0.110 |
Why?
|
Decision Making | 2 | 2020 | 3887 | 0.110 |
Why?
|
Age Factors | 2 | 2020 | 18355 | 0.110 |
Why?
|
Alcoholism | 1 | 2024 | 1907 | 0.110 |
Why?
|
Models, Economic | 1 | 2017 | 712 | 0.110 |
Why?
|
Vulnerable Populations | 1 | 2018 | 685 | 0.110 |
Why?
|
Cholesterol | 1 | 2022 | 2922 | 0.110 |
Why?
|
Societies, Medical | 3 | 2021 | 3740 | 0.100 |
Why?
|
Consensus | 1 | 2020 | 2954 | 0.100 |
Why?
|
Monitoring, Physiologic | 1 | 2019 | 1738 | 0.100 |
Why?
|
Prescription Drugs | 1 | 2018 | 593 | 0.100 |
Why?
|
Physician's Role | 1 | 2018 | 942 | 0.100 |
Why?
|
Insurance, Health | 2 | 2020 | 2492 | 0.090 |
Why?
|
Health Surveys | 1 | 2021 | 4036 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 1 | 2019 | 1854 | 0.090 |
Why?
|
Data Interpretation, Statistical | 1 | 2020 | 2715 | 0.090 |
Why?
|
Life Style | 1 | 2021 | 3833 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2020 | 1438 | 0.090 |
Why?
|
Pregnancy | 2 | 2022 | 29140 | 0.090 |
Why?
|
Ambulatory Care | 1 | 2020 | 2707 | 0.080 |
Why?
|
Core Binding Factor Alpha 3 Subunit | 1 | 2008 | 56 | 0.080 |
Why?
|
Particulate Matter | 1 | 2020 | 2529 | 0.080 |
Why?
|
Pyridines | 1 | 2020 | 2827 | 0.080 |
Why?
|
Physician-Patient Relations | 2 | 2020 | 3229 | 0.080 |
Why?
|
Data Collection | 1 | 2017 | 3339 | 0.080 |
Why?
|
Antiviral Agents | 1 | 2020 | 2984 | 0.080 |
Why?
|
Length of Stay | 1 | 2020 | 6311 | 0.070 |
Why?
|
Medication Adherence | 1 | 2018 | 2063 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2024 | 21733 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2020 | 13980 | 0.070 |
Why?
|
Students, Medical | 1 | 2019 | 1862 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2020 | 5316 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2020 | 12020 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12354 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2016 | 2265 | 0.070 |
Why?
|
Risk Factors | 2 | 2023 | 72252 | 0.060 |
Why?
|
Chronic Disease | 1 | 2020 | 9139 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15067 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5319 | 0.060 |
Why?
|
Infant, Newborn | 1 | 2023 | 25609 | 0.060 |
Why?
|
Phenotype | 1 | 2021 | 16361 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2021 | 57744 | 0.060 |
Why?
|
Cost Savings | 2 | 2018 | 925 | 0.050 |
Why?
|
Interviews as Topic | 2 | 2020 | 2538 | 0.050 |
Why?
|
Needs Assessment | 2 | 2018 | 1146 | 0.050 |
Why?
|
Prospective Studies | 3 | 2021 | 53250 | 0.050 |
Why?
|
Melanoma | 1 | 2020 | 5508 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2016 | 4370 | 0.050 |
Why?
|
Vaccination | 2 | 2023 | 3275 | 0.050 |
Why?
|
Legislation, Pharmacy | 1 | 2020 | 2 | 0.050 |
Why?
|
Minocycline | 1 | 2022 | 163 | 0.050 |
Why?
|
Current Procedural Terminology | 1 | 2021 | 92 | 0.050 |
Why?
|
Immunocompetence | 1 | 2020 | 136 | 0.040 |
Why?
|
Economics, Pharmaceutical | 1 | 2020 | 87 | 0.040 |
Why?
|
Injections, Intralesional | 1 | 2020 | 276 | 0.040 |
Why?
|
Macrolides | 1 | 2020 | 201 | 0.040 |
Why?
|
Tretinoin | 1 | 2022 | 517 | 0.040 |
Why?
|
Photography | 1 | 2022 | 519 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 29052 | 0.040 |
Why?
|
Fees, Pharmaceutical | 1 | 2018 | 64 | 0.040 |
Why?
|
Philadelphia | 1 | 2018 | 267 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2023 | 3921 | 0.040 |
Why?
|
Review Literature as Topic | 1 | 2019 | 336 | 0.040 |
Why?
|
Health Personnel | 2 | 2023 | 3217 | 0.040 |
Why?
|
Temperature | 1 | 2023 | 2202 | 0.040 |
Why?
|
Attitude | 1 | 2022 | 775 | 0.040 |
Why?
|
Health Plan Implementation | 1 | 2020 | 351 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39001 | 0.040 |
Why?
|
Patient Protection and Affordable Care Act | 2 | 2016 | 1209 | 0.030 |
Why?
|
Cities | 1 | 2018 | 512 | 0.030 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2020 | 397 | 0.030 |
Why?
|
Patients | 1 | 2023 | 899 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2019 | 13691 | 0.030 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2019 | 469 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 1340 | 0.030 |
Why?
|
Steroids | 1 | 2020 | 930 | 0.030 |
Why?
|
Minority Groups | 1 | 2022 | 1222 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2020 | 847 | 0.030 |
Why?
|
Hospitalization | 1 | 2014 | 10259 | 0.030 |
Why?
|
Rheumatology | 1 | 2020 | 576 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2617 | 0.030 |
Why?
|
Androgen Antagonists | 1 | 2023 | 1376 | 0.030 |
Why?
|
Observer Variation | 1 | 2020 | 2592 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 574 | 0.030 |
Why?
|
Drug Resistance, Bacterial | 1 | 2020 | 1030 | 0.030 |
Why?
|
Schools, Medical | 1 | 2019 | 879 | 0.030 |
Why?
|
Drug Approval | 1 | 2018 | 742 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2008 | 4839 | 0.030 |
Why?
|
Perception | 1 | 2018 | 1198 | 0.020 |
Why?
|
Fee-for-Service Plans | 1 | 2016 | 694 | 0.020 |
Why?
|
Faculty, Medical | 1 | 2019 | 1181 | 0.020 |
Why?
|
Communicable Diseases | 1 | 2018 | 880 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2760 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2008 | 399 | 0.020 |
Why?
|
Infant | 2 | 2020 | 35122 | 0.020 |
Why?
|
Child, Preschool | 2 | 2020 | 40964 | 0.020 |
Why?
|
Ovary | 1 | 2008 | 980 | 0.010 |
Why?
|
Cytoplasm | 1 | 2008 | 1536 | 0.010 |
Why?
|
Gene Silencing | 1 | 2008 | 1537 | 0.010 |
Why?
|
Up-Regulation | 1 | 2008 | 4221 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2008 | 3504 | 0.010 |
Why?
|
Internship and Residency | 1 | 2019 | 5787 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2008 | 11360 | 0.010 |
Why?
|
Cell Line | 1 | 2008 | 15993 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2008 | 13028 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2008 | 8430 | 0.010 |
Why?
|